The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Complete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel via Π–Π Stacking Stabilized Polymeric Micelles
Open accessAbstract
Treatment of cancer patients with taxane-based chemotherapeutics, such as paclitaxel (PTX), is complicated by their narrow therapeutic index. Polymeric micelles are attractive nanocarriers for tumor-targeted delivery of PTX, as they can be tailored to encapsulate large amounts of hydrophobic drugs and achiv prolonged circulation kinetics. As a result, PTX deposition in tumors is increased, while drug exposure to healthy tissues is reduced. However, many PTX-loaded micelle formulations suffer from low stability and fast drug release in the circulation, limiting their suitability for systemic drug targeting. To overcome these limitations, we have developed PTX-loaded micelles which are stable without chemical cross-linking and covalent drug attachment. These micelles are characterized by excellent loading capacity and strong drug retention, attributed to π-π stacking interaction between PTX and the aromatic groups of the polymer chains in the micellar core. The micelles are based on methoxy poly(ethylene glycol)-b-(N-(2-benzoyloxypropyl)methacrylamide) (mPEG-b-p(HPMAm-Bz)) block copolymers, which improved the pharmacokinetics and the biodistribution of PTX, and substantially increased PTX tumor accumulation (by more than 2000%; as compared to Taxol or control micellar formulations). Improved biodistribution and tumor accumulation were confirmed by hybrid μCT-FMT imaging using near-infrared labeled micelles and payload. The PTX-loaded micelles were well tolerated at different doses, while they induced complete tumor regression in two different xenograft models (i.e., A431 and MDA-MB-468). Our findings consequently indicate that π-π stacking-stabilized polymeric micelles are promising carriers to improve the delivery of highly hydrophobic drugs to tumors and to increase their therapeutic index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910
Owen, S. C., Chan, D. P. Y., & Shoichet, M. S. (2012) · Nano Today · doi:10.1016/j.nantod.2012.01.002 · Cited by 911
Progress of drug-loaded polymeric micelles into clinical studies
Cabral, H., & Kataoka, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.042 · Cited by 837
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
Kim, S. C., Kim, D. W., Shim, Y. H., Bang, J. S., Oh, H. S., Kim, S. W., & Seo, M. H. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00275-9 · Cited by 734
Polymeric micelles drug delivery system in oncology
Gong, J., Chen, M., Zheng, Y., Wang, S., & Wang, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.012 · Cited by 570
Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541
Kwon, G., Suwa, S., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (1994) · Journal of Controlled Release · doi:10.1016/0168-3659(94)90118-x · Cited by 409
Chen, H., Kim, S., He, W., Wang, H., Low, P. S., Park, K., & Cheng, J.-X. (2008) · Langmuir · doi:10.1021/la703570m · Cited by 311
Shi, Y., van Steenbergen, M. J., Teunissen, E. A., Novo, L., Gradmann, S., Baldus, M., van Nostrum, C. F., & Hennink, W. E. (2013) · Biomacromolecules · doi:10.1021/bm400234c · Cited by 222
Self-citationGu, Y., Zhong, Y., Meng, F., Cheng, R., Deng, C., & Zhong, Z. (2013) · Biomacromolecules · doi:10.1021/bm400615n · Cited by 187
Drug-induced morphology switch in drug delivery systems based on poly(2-oxazoline)s
Schulz, A., Jaksch, S., Schubel, R., Wegener, E., Di, Z., Han, Y., Meister, A., Kressler, J., Kabanov, A. V., Luxenhofer, R., et al. (2014) · ACS Nano · doi:10.1021/nn406388t · Cited by 142
Cited by
Strategies to improve micelle stability for drug delivery
Lu, Y., Zhang, E., Yang, J., & Cao, Z. (2018) · Nano Research · doi:10.1007/s12274-018-2152-3 · Cited by 530
Applications of π-π stacking interactions in the design of drug-delivery systems
Zhuang, W.-R., Wang, Y., Cui, P.-F., Xing, L., Lee, J., Kim, D., Jiang, H.-L., & Oh, Y.-K. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.014 · Cited by 508
The battle of “nano” paclitaxel
Sofias, A. M., Dunne, M., Storm, G., & Allen, C. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.02.003 · Cited by 401
Self-citationCheng, Y.-H., He, C., Riviere, J. E., Monteiro-Riviere, N. A., & Lin, Z. (2020) · ACS Nano · doi:10.1021/acsnano.9b08142 · Cited by 362
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113891 · Cited by 289
Metadata
- Authors
- Shi, Y., van der Meel, R., Theek, B., Oude Blenke, E., Pieters, E. H. E., Fens, M. H. A. M., Ehling, J., Schiffelers, R. M., Storm, G., van Nostrum, C. F., Lammers, T., & Hennink, W. E.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-04-06
- Volume
- 9
- Issue
- 4
- Pages
- 3740-3752
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W1967104248
- Cited by
- 214
- References
- 15
- FWCI
- 9.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.